Announcements Trials
Browse Landscape

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Neoplasms 19Stomach Neoplasms 15Colorectal Neoplasms 15Lung Neoplasms 13Endometrial Neoplasms 13Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 10Colonic Neoplasms 9Carcinoma, Hepatocellular 9Oropharyngeal Neoplasms 6Neoplasm Metastasis 6Multiple Myeloma 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Rectal Neoplasms 5Mouth Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Head and Neck Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4

Interventions

Ibandronic Acid 8Gemcitabine 8Doxorubicin 6Cyclophosphamide 6Zoledronic Acid 5Radiation 4Nivolumab 4Irinotecan 4pembrolizumab 3Vincristine 3Temozolomide 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Docetaxel 3Denosumab 3Cisplatin 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3regorafenib 2pegfilgrastim 2Tranexamic Acid 2Trabectedin 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Quality of Life 2Proton Therapy 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Neoplasms × Observation × Clear all
NCT02677961 2026-02-11

An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry

Ohio State University Comprehensive Cancer Center

Recruiting
1,500 enrolled
Sarcoma

Bone Neoplasms, Sarcoma, Neoplasms, Connective and Soft Tissue

NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡